High Sustained Virologic Response (SVR) Among Genotype I Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated with Boceprevir (BOC) Plus Peginterferon Alfa-2A/Ribavirin

被引：0
|
作者：
Flamm, Steven L.
Lawitz, Eric J.
Jacobson, Ira M.
Rubin, Raymond A.
Bourliere, Marc
Hezode, C.
Vierling, J.
Niederau, Claus
Sherman, Morris
Goteti, Venkata S.
Vilchez, Regis A.
Brass, Clifford A.
Albrecht, Janice K.
Poordad, Fred
机构：
来源：
GASTROENTEROLOGY | 2011年 / 140卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [21] PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 WHEN TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (PR)
    Reddy, K. R.
    Bruno, S.
    Rossaro, L.
    Ravendhran, N.
    Pauly, M. P.
    Boparai, N.
    Sniukiene, V.
    Brass, C. A.
    Albrecht, J. K.
    Poordad, F.
    Jacobson, I. M.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S190 - S190
  • [22] A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin
    Swain, Mark G.
    Lai, Ming-Yang
    Shiffman, Mitchell L.
    Cooksley, W. Graham E.
    Zeuzem, Stefan
    Dieterich, Douglas T.
    Abergel, Armand
    Pessoa, Mario G.
    Lin, Amy
    Tietz, Andreas
    Connell, Edward V.
    Diago, Moises
    GASTROENTEROLOGY, 2010, 139 (05) : 1593 - 1601
  • [23] Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders
    Jensen, Donald
    Sherman, Kenneth E.
    Hezode, Christophe
    Pol, Stanislas
    Zeuzem, Stefan
    de Ledinghen, Victor
    Tran, Albert
    Elkhashab, Magdy
    Younes, Ziad H.
    Kugelmas, Marcelo
    Mauss, Stefan
    Everson, Gregory
    Luketic, Velimir
    Vierling, John
    Serfaty, Lawrence
    Brunetto, Maurizia
    Heo, Jeong
    Bernstein, David
    McPhee, Fiona
    Hennicken, Delphine
    Mendez, Patricia
    Hughes, Eric
    Noviello, Stephanie
    JOURNAL OF HEPATOLOGY, 2015, 63 (01) : 30 - 37
  • [24] Clinical decision tool for predicting treatment week eight response and sustained virologic response in patients treated with boceprevir (BOC) plus peginterferon alfa and ribavirin (PR)
    Devine, S.
    Kattan, M. W.
    Muir, A. J.
    Pedicone, L.
    Poordad, F.
    Poynard, T.
    Sulkowski, M. S.
    Thompson, A. J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 159 - 159
  • [25] Clinical Decision Tool for Predicting Treatment Week Eight Response and Sustained Virologic Response in Patients Treated with Boceprevir (BOC) Plus Peginterferon Alfa and Ribavirin (PR)
    Devine, Scott
    Kattan, Michael W.
    Muir, Andrew J.
    Pedicone, Lisa
    Poordad, Fred
    Poynard, Thierry
    Sulkowski, Mark S.
    Thompson, Alexander J.
    HEPATOLOGY, 2012, 56 : 1052A - 1052A
  • [26] Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial
    Pessoa, Mario G.
    Cheinquer, Hugo
    Almeida, Paulo R. L.
    Silva, Giovanni F.
    Lima, Maria Patelli J. S.
    Parana, Raymundo
    Lacerda, Marco A.
    Parise, Edison R.
    Pernambuco, Jose R. B.
    Pedrosa, Suelene S.
    Teixeira, Rosangela
    Sette, Hoel, Jr.
    Tatsch, Fernando
    ANNALS OF HEPATOLOGY, 2012, 11 (01) : 52 - 61
  • [27] Clinical trial:: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin
    Bain, V. G.
    Lee, S. S.
    Peltekian, K.
    Yoshida, E. M.
    Deschenes, M.
    Sherman, M.
    Bailey, R.
    Witt-Sullivan, H.
    Balshaw, R.
    Krajden, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (01) : 43 - 50
  • [28] SUSTAINED VIROLOGICAL RESPONSE (SVR) IN HCV TREATMENT-EXPERIENCED PATIENTS AFTER TRIPLE THERAPY WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN IN A REAL-LIFE SETTING
    Boeker, K. H. W.
    Link, R.
    Baumgarten, A.
    Stoehr, A.
    Heyne, R.
    Roessle, M.
    Schott, E.
    Ullrich, R.
    Erren, P.
    Herold, C.
    Schmidt, W.
    Simon, K. -G.
    Geissler, M.
    Schiffelholz, W.
    Alshuth, U.
    Hueppe, D.
    Mauss, S.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S462 - S463
  • [29] BASELINE FACTORS ASSOCIATED WITH SUSTAINED VIROLOGIC RESPONSE (SVR) IN PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS PLUS PEGINTERFERON ALFA-2a (40KD) AND RIBAVIRIN
    Christensen, S.
    Boeker, K. H. W.
    Eisenbach, C.
    Schuchmann, M.
    Lutz, T.
    Heyne, R.
    Moog, G.
    Mauss, S.
    Jung, M. -C.
    Teuber, G.
    Emke, F.
    Naumann, U.
    Doss, M. Frank
    von Lucadou, A.
    Alshuth, U.
    Hueppe, D.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S465 - S465
  • [30] Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin
    Jensen, DM
    Marcellin, P
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2005, 17 (09) : 899 - 904
12345